Medicilon was Elected as the Director Unit of The Listed Companies Association of Shanghai

On November 10, 2022, the Listed Companies Association of Shanghai held the 4th  member meeting of the association and the 1st meeting of council of the association through the online platform of East Money information.  The meeting was presided over by Yuan Yi, Secretary of the Association, and supervised by the Shanghai Oriental Notary Public Office.

During the meeting, Shanghai Medicilon Inc. (Medicilon) was elected as the director unit of the Listed Companies Association of Shanghai.

As a one-stop pharmaceutical preclinical R&D service platform, Medicilon is committed to providing a full range of preclinical research services to global pharmaceutical companies, research institutions and scientific researchers, and promoting the process of new drug research.  After 18 years of hard work, Medicilon has always explored the road of cutting-edge technological innovation, focusing on breaking through the key technological bottlenecks in the development of the pharmaceutical industry, and further research the new technology such as nucleic acid drugs, cellular immunity, mRNA vaccines, PROTACs, ADCs, and bi/multispecific antibodies.  With efficient, high-quality, and cost-effective R&D services, Medicilon provides new drug R&D services to more than 1,710 clients worldwide.  Medicilon participated in the research and development of 268 new drug projects that were approved for clinical trials.  This proved that Medicilon won the trust from the clients and long-term strategic collaboration.